Literature DB >> 7116768

Effect of rifampicin and isoniazid on vitamin D metabolism.

M J Brodie, A R Boobis, C J Hillyard, G Abeyasekera, J C Stevenson, I MacIntyre, B K Park.   

Abstract

Rifampicin, 600 mg, and isoniazid, 300 mg daily for 14 days, reduced circulating levels of 25-hydroxy vitamin D (25-OHD) and 1 alpha, 25-dihydroxy vitamin D (1,25(OH)2D) by 34% (P less than 0.01) and 23% (P less than 0.05) in eight healthy subjects. This was accompanied by a rise in parathyroid hormone (PTH) of 57% (P less than 0.01), but not by a fall in serum calcium or phosphate levels. There was induction of endogenous cortisol oxidation in all subjects, but only in four fast acetylators was there a concomitant increase in antipyrine elimination. In the four slow acetylators antipyrine metabolism was inhibited after the first dose of the drugs. In nine tuberculous patients followed serially there was a fall in 25-OHD and 1,25 (OD)2D and a rise in PTH at the end of 1 mo (P less than 0.05). After 6 mo therapy 25-OHD concentration was further reduced (P less than 0.01), but there was no significant change in 1,25 (OH)2D or PTH levels. Combination treatment with rifampicin and isoniazid perturbs vitamin D metabolism, but less than might have been predicted from reports on each drug given alone. Nevertheless, tuberculous patients with already compromised calcium homeostasis receiving this combination of drugs should be carefully monitored.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7116768     DOI: 10.1038/clpt.1982.197

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  27 in total

Review 1.  New antituberculous drugs in development.

Authors:  Umesh G Lalloo; Anish Ambaram
Journal:  Curr HIV/AIDS Rep       Date:  2010-08       Impact factor: 5.071

2.  Remission of hypercalciuria in patients with tuberculosis after treatment.

Authors:  M E Martinez; J Gonzalez; M J Sanchez-Cabezudo; J M Peña; J J Vazquez
Journal:  Calcif Tissue Int       Date:  1996-07       Impact factor: 4.333

3.  Recognizing the musculoskeletal manifestations of vitamin D deficiency.

Authors:  Andrea N Jones; Karen E Hansen
Journal:  J Musculoskelet Med       Date:  2009-10

Review 4.  Calcium and vitamin D metabolism in granulomatous diseases.

Authors:  M Fuss; T Pepersack; C Gillet; R Karmali; J Corvilain
Journal:  Clin Rheumatol       Date:  1992-03       Impact factor: 2.980

Review 5.  The SLC34 family of sodium-dependent phosphate transporters.

Authors:  Carsten A Wagner; Nati Hernando; Ian C Forster; Jürg Biber
Journal:  Pflugers Arch       Date:  2013-12-19       Impact factor: 3.657

6.  An inducible cytochrome P450 3A4-dependent vitamin D catabolic pathway.

Authors:  Zhican Wang; Yvonne S Lin; Xi Emily Zheng; Tauri Senn; Takanori Hashizume; Michele Scian; Leslie J Dickmann; Sidney D Nelson; Thomas A Baillie; Mary F Hebert; David Blough; Connie L Davis; Kenneth E Thummel
Journal:  Mol Pharmacol       Date:  2011-12-28       Impact factor: 4.436

Review 7.  Pharmacokinetic drug interactions with rifampicin.

Authors:  K Venkatesan
Journal:  Clin Pharmacokinet       Date:  1992-01       Impact factor: 6.447

8.  Nuclear xenobiotic receptor pregnane X receptor locks corepressor silencing mediator for retinoid and thyroid hormone receptors (SMRT) onto the CYP24A1 promoter to attenuate vitamin D3 activation.

Authors:  Yoshihiro Konno; Susumu Kodama; Rick Moore; Nobuhiro Kamiya; Masahiko Negishi
Journal:  Mol Pharmacol       Date:  2008-11-03       Impact factor: 4.436

9.  Enhancement of hepatic 4-hydroxylation of 25-hydroxyvitamin D3 through CYP3A4 induction in vitro and in vivo: implications for drug-induced osteomalacia.

Authors:  Zhican Wang; Yvonne S Lin; Leslie J Dickmann; Emma-Jane Poulton; David L Eaton; Johanna W Lampe; Danny D Shen; Connie L Davis; Margaret C Shuhart; Kenneth E Thummel
Journal:  J Bone Miner Res       Date:  2013-05       Impact factor: 6.741

10.  Pharmacogenetic differences in the inhibitory effect of cimetidine on the metabolism of antipyrine.

Authors:  B Gachályi; A Vas; K Csillag; B Nagy; F Kocsis; A Káldor
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.